Abstract: The present invention relates generally to processes for adding a chemical composition to a produced water mixture upstream of a pad related to a well to be fracked. The added chemical composition comprises a drag reducing agent, or a biocide, or a scale inhibitor, or any combination thereof. The produced water mixture comprising the added chemical composition may then be transferred in a pipeline to the well to be fracked. This offers a number of advantages that may include, for example, reducing the footprint at the pad, improved efficacy of biocide, reduced time to transfer produced water, and/or reduced pumping time during the fracking.

Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

Abstract: Aspects of the present disclosure generally relate to magnetic recording heads (such as write heads of data storage devices) that include multilayer structures to facilitate targeted switching and relatively low coercivity. In one or more embodiments, a magnetic recording head includes an iron-cobalt (FeCo) layer having a crystalline structure that is a cubic lattice structure, a first crystalline layer formed of a first material, and a second crystalline layer between the first crystalline layer and the FeCo layer. The second crystalline layer is formed of a second material different from the first material, and the second crystalline layer interfaces both the FeCo layer and the first crystalline layer. The crystalline structure of the FeCo layer has a texture of <100>.

Abstract: The present disclosure provides systems and methods for sample analysis. The system comprises a container. The container comprises a sample receptacle and a cap, and the cap comprises a reservoir for retaining a composition, a first piercing member and a first pierceable barrier for sealing said composition within said reservoir. There is also provided a method for sample analysis.

Abstract: Methods of sequencing molecules based on luminescence lifetimes and/or intensities are provided. In some aspects, methods of sequencing nucleic acids involve determining the luminescence lifetimes, and optionally luminescence intensities, of a series of luminescently labeled nucleotides incorporated during a nucleic acid sequencing reaction.

Abstract: Hydroxide-exchange membranes (HEMs) and hydroxide-exchange ionomers (HEIs) are provided which include polymers with oxidation resistant groups. The attachment of the oxidation resistant groups to the polymer backbone allows fine-tuning of the mechanical properties of the membrane and incorporation of alkaline stable cations, such as imidazoliums, phosphoniums and ammoniums, and provides enhanced stability to the polymer. HEMs/HEIs formed from these polymers exhibit superior chemical stability, anion conductivity, decreased water uptake, good solubility in selected solvents, and improved mechanical properties in an ambient dry state as compared to conventional HEM/HEIs. The HEMs exhibit enhanced stability in a highly oxidative environment.

Abstract: Compositions useful for the detection of single molecules in a sample are provided. In some aspects, the disclosure provides a nucleotide connected to a nucleic acid comprising a FRET label comprising at least three luminescent molecules. In some embodiments, the nucleic acids described herein comprise one or more structural features that provide enhanced fluorescence intensity. In some aspects, methods of sequencing using the labeled nucleotides of the disclosure are provided.

Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

Abstract: A semiconductor device system comprises an integrated circuit (IC) die. The IC die is configured to operate in a first operating mode during a first period, and a second operating mode during a second period. The first period is associated with enabling an element of the IC die and a first amount of voltage droop. The second period occurs after the first period and is associated with a second amount of voltage droop. The second amount of voltage droop is less than the first amount of voltage droop.

Abstract: The present disclosure relates to methods and intermediates useful for preparing a compound of formula I: or a co-crystal, solvate, salt or combination thereof.

Abstract: The present disclosure relates to hair coloring base compositions and ready-to-use hair coloring compositions comprising 2-methoxymethyl-P-phenylenediamine, an oxidative dye precursor. The hair coloring base composition is mixed with a developer composition to form a ready-to-use hair coloring composition having a lower than typical pH, 7. These compositions are effective for coloring hair, especially beard hair. The color imparted to the hair is long-lasting (tenacious) and skin sensitivity due to the coloring process is minimized or prevented. Methods for making the composition and methods for coloring hair, especially beard hair, are also disclosed.

Abstract: Compositions useful for the detection of single molecules in a sample are provided. In some aspects, the disclosure provides a nucleic acid connected to a nucleotide and two or more luminescent labels. In some embodiments, the nucleic acids described herein comprise one or more structural features that provide enhanced fluorescence intensity. In some aspects, methods of sequencing using the labeled nucleotides of the disclosure are provided.

Abstract: A method for generating a diagnosis via a digital health application includes receiving, by a digital health application, a request for a diagnosis. A digital health application selects a plurality of questions based on the initial complaint, an order of presenting each of the plurality of questions, the order associated with the plurality of questions. The digital health application displays, to a user of the digital health application, in the associated order, each of the plurality of questions. The digital health application receives user input responsive to the questions. The digital health application determines a diagnosis and modifies a user interface to display an identification of the determined diagnosis. The digital health application requests an indication of whether the user of the digital health application accepts the diagnosis. The digital health application requests an indication of whether to establish a consultation with a medical professional to discuss the diagnosis.

Abstract: A computer-implemented system for managing electronic medical records may include one or more processors configured to receive, via a user interface of a user device, a user input for adding a new trial and create a new trial portfolio based on the received user input. The portfolio may comprise patient eligibility criteria associated with the new trial. The one or more processors may also be configured to automatically create a patient-trial matching algorithm for the new trial based on the trial eligibility criteria and determine, based on electronic patient medical records associated with a plurality of patients and the patient-trial matching algorithm, at least one suggested patient determined to be eligible for the new trial. The one or more processors may further be configured to transmit, to the user device, instructions for displaying information representing the at least one suggested patient in the user interface.